This analysis evaluates the company's strategy and key strengths, weaknesses,
opportunities and threats, and provides an overview of the company's
historical and forecast financial performance. The report also gives an
in-depth analysis of the company's key prescription pharmaceutical product,
and provides a forecast sales performance for this drug.
Features and benefits
Gain insight into Regeneron's strategic outlook
Analyze company sales forecasts by product
Highlights
In November 2011, the FDA approved Regeneron's second drug, Eylea, for the
treatment of wet AMD. Eylea garnered sales of $24.8m in Q4 2011 and $124m in
Q1 2012. Approval is expected in the EU in late 2012 or early 2013.
Datamonitor conducted a survey of 31 retinal specialists in the US to assess
opinions of Eylea and current use of wet AMD agents.
Your key questions answered
Assess Eylea's prospects in the wet AMD market, going up against Roche's
Lucentis
Gain insight into Regeneron's other pipeline products, including: Arcalyst
for prevention of gout flares and Zaltrap for second-line colorectal cancer
Benchmark Regeneron's performance against key rivals in the prescription
pharmaceutical sector
Table of Contents
Table of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus
EXECUTIVE SUMMARY
Company introduction
Recent developments
Corporate relationships
Bayer
Astellas
Novartis
Roche/Genentech
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
SALES AND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
Eylea (intraocular aflibercept; VEGF Trap-Eye)
Disease background
CATT trial
Retinal vein occlusion
Diabetic macular edema
Wet AMD clinical trials
Opinions of Eylea
Use in retinal vein occlusion and diabetic macular edema
BRVO trial
DME trial
Current use of anti-VEGF agents in RVO and DME
Key forecasting assumptions
CRVO
BRVO
DME
Zaltrap (intravenous aflibercept; VEGF-Trap)
Colorectal cancer clinical trials
Several factors may impact Zaltrap's uptake in the second-line setting
Sanofi's presence in the colorectal cancer market will aid
commercialization of Zaltrap
Key forecasting assumptions
Arcalyst (rilonacept)
Arcalyst CAPS sales to remain flat through forecast period
Gout background
Gout clinical trials
Approval of Arcalyst for the prevention of gout flares appears unlikely
following negative FDA panel vote
Sarilumab (REGN88; IL-6R antibody)
REGN727 (SAR236553; PCSK9 antibody)
Regeneron and Sanofi have not disclosed plans for REGN727 Phase III
development
Figure: In October 2011 (immediately prior to the approval of Eylea), what
percentage of your treated wet AMD patients were receiving the following
treatments?
Figure: Following the 2-year results of the CATT trial, how do you view
Avastin versus Lucentis in terms of efficacy/safety?
Figure: Based on your knowledge of the three anti-VEGF agents, please rate
them on a scale from 1 to 5 on the following attributes, where 1=poor and
5=excellent.
Figure: Of the patients to whom you have administered Eylea, what
percentage falls into each of the following categories? (Weighted average)
Figure: So far this year, what percentage of your newly diagnosed patients
received the following agents as their first-line therapy? Three years from
now, what percentage of your newly diagnosed patients do you expect will
receive the following agents as their first-line therapy?
Figure: Of your patients failing their first-line therapy, what percentage
do you expect will receive Avastin, Lucentis, or Eylea as a second-line
therapy?
Figure: Of your CRVO/BRVO/DME patients, what percentages are currently
treated with the following?
Regeneron Pharmaceuticals, Inc.: PharmaVitae Report published by Datamonitor in May 31, 2012. This report consists of Pages: 55 and the price starts from US $ 5700.
